Table 2.
Pathways analysis of transcriptomic data associated with liver fibrosis progression in thioacetamide (TAA) model.
| Pathway ID | Pathway term | DifGene | P-value | FDR | Enrichment |
|---|---|---|---|---|---|
| PATH:04512 | ECM-receptor interaction | 29 | 5.47E-12 | 1.37E-09 | 4.28409091 |
| PATH:04510 | Focal adhesion | 45 | 4.83E-11 | 6.06E-09 | 2.87642046 |
| PATH:04151 | PI3K-Akt signaling pathway | 54 | 2.32E-07 | 1.16E-05 | 2.04545455 |
| PATH:05205 | Proteoglycans in cancer | 39 | 6.50E-07 | 2.33E-05 | 2.29434835 |
| PATH:04390 | Hippo signaling pathway | 27 | 2.62E-05 | 0.00065699 | 2.33102125 |
| PATH:05200 | Pathways in cancer | 44 | 0.00011124 | 0.00232667 | 1.7781155 |
| PATH:04514 | Cell adhesion molecules (CAMs) | 26 | 0.0001237 | 0.00238836 | 2.17409949 |
| PATH:04360 | Axon guidance | 23 | 0.00014333 | 0.00256977 | 2.28205563 |
| PATH:04010 | MAPK signaling pathway | 37 | 0.00025801 | 0.00380942 | 1.81524656 |
| PATH:04350 | TGF-beta signaling pathway | 17 | 0.00028484 | 0.00397196 | 2.53958121 |
| PATH:04810 | Regulation of actin cytoskeleton | 31 | 0.00046624 | 0.0061593 | 1.87345041 |
| PATH:04310 | Wnt signaling pathway | 24 | 0.00068317 | 0.00784191 | 2.01956272 |
Note: Axon guidance signaling are listed within the significantly upregulated signaling pathways (partial).